Search Results for “EC” – Page 368 – media

Oral health worsens in morbidly obese people before and after bariatric surgery

Oral health deteriorates in morbidly obese people on a diet in preparation for bariatric surgery and patients who have undergone the procedure, with increasing caries, gingivitis and periodontitis. This is the conclusion of a study conducted by researchers at the Federal University of São Paulo (UNIFESP) in Brazil. Articles on the study are published in the Journal of Oral Rehabilitation and Clinical Oral Investigations, stressing the importance of participation by a dentist in the assessment of bariatric patients. The study was funded by FAPESP (projects 17/26400-6 and 16/10940-9), following 100 patients divided into two groups (dietary counseling and gastroplasty) at the Bariatric Clinic in Piracicaba, São Paulo state. The clinic performs some 50 such operations per month, mainly under the auspices of the SUS (“Sistema Único de Saúde”), Brazil’s national health service. Questionnaires, oral examinations, saliva samples and cheek swabs were analyzed to determine dietary changes, weight loss, inflammatory markers, ...
- Source: drugdu
- 116
- September 8, 2023
Guardant abandons cancer blood test trial early, restates confidence in product line

Dive Brief Guardant Health has stopped a trial of a minimum residual disease (MRD) test early after seeing the results of an interim analysis. The study, called COBRA, was evaluating the ability of Guardant’s MRD blood test to improve outcomes in patients with stage II colon cancer after surgery. Patients underwent circulating tumor deoxyribonucleic acid testing to inform further treatment. Guardant, which collaborated with NRG Oncology on the study, has yet to share data from the trial but confirmed it stopped early after the news leaked on social media. Shares in Guardant fell around 13% to below $35 on Friday. Dive Insight Guardant and NRG Oncology, a clinical trial group funded by the National Cancer Institute, began the trial in 2020 on the strength of evidence that the LUNAR-1 blood test may help identify patients who are likely to benefit from chemotherapy after surgery. The test, the product of a ...
- Source: drugdu
- 122
- September 8, 2023
【Expert Q&A】How do I get started in the pharmaceutical intermediates business?

Entering the pharmaceutical intermediates business is a challenge that requires a wide range of specialized knowledge and experience, especially if you don’t have an extensive network in this field. Here are some suggestions to help you get started and succeed in your business: I. Basic Preparation Market Research: Understand industry trends, target customers, competitors, and market demand. Financing and Budget: Ensure you have enough capital to operate, including for production, sales, and marketing. Licensing and Compliance: Know and adhere to all relevant laws and regulations, including obtaining necessary permits and certifications. II. Technology and Production R&D Capability: Have or partner with reliable R&D institutions to develop and improve products. Quality Control: Establish strict quality control procedures. Supply Chain Management: Find reliable raw material suppliers and establish robust logistics and inventory management systems. III. Sales and Marketing Sales Team: Establish or hire an experienced sales team. Online Marketing: Utilize websites, social ...
- Source: drugdu
- 246
- September 7, 2023
Licensing and Compliance market research pharmaceutical intermediates
Medtronic sued for allegedly sharing ‘treasure trove’ of diabetes patient data with Google

Dive Brief A plaintiff has accused Medtronic of sharing user data for its InPen diabetes management system with companies including Google. The lawsuit alleges that Medtronic’s MiniMed business used digital platforms to acquire “a treasure trove of personal data” and shared the information with third parties to increase revenue and profits. According to the plaintiff in the proposed class action lawsuit, the disclosures to Google are “particularly problematic” because his use of Gmail meant his personal information was “automatically linked to his real identity.” Dive Insight The case centers on the app that accompanies Medtronic’s smart insulin pen. Medtronic created the app to help patients record their insulin doses, receive reminders and share data with their healthcare team. The use of the data is covered by Medtronic’s notice of privacy practices. According to the lawsuit, the company has used the data in ways that are beyond the terms covered in ...
- Source: drugdu
- 114
- September 7, 2023
New UK study suggests brain fog after COVID-19 is linked to blood clots

A new UK study led by a research team from the University of Oxford and the University of Leicester has suggested that blood clots in the brain or the lungs could potentially explain common symptoms of long COVID. The post-hospitalisation COVID-19 study (PHosp-COVID), published in Nature Medicine, found that people admitted to hospital due to COVID-19 had higher levels of the fibrinogen protein and protein fragment D-dimer, which can cause excess clotting. Excess blood clotting was found to be a possible cause for symptoms like brain fog and fatigue in long COVID. Previous research has found that blood clotting can cause a lack of blood supply to the brain or cause fatigue, which both can cause cognitive problems. People with long COVID can have a wide range of symptoms that last weeks, months, or even years after having a SARS-CoV-2 infection, and for some, it can result in disability or ...
- Source: drugdu
- 185
- September 7, 2023
Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Nestlé has unloaded its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer after previously spending billions on the treatment’s acquisition. The company will receive undisclosed milestone payments and ongoing royalties from Stallergenes Greer as part of the deal, according to the 4 September announcement. In August 2020, Nestlé acquired Palforzia through its $2.6bn takeover of Aimmune Therapeutics, the original developer of the peanut allergy treatment. Prior to this, Nestlé invested $473m in Aimmune over several years. Most recently, Aimmune received $200m from Nestlé in February 2020, only days after the US Food and Drug Administration (FDA) approved Palforzia as a peanut allergy treatment for children ages four years through 17. The European Commission approved the drug in the same patient group in December 2020. While the drug was approved for use in children, the drug can also be used in those aged 18 and older in combination with a ...
- Source: drugdu
- 220
- September 7, 2023
Years after $2B buyout, Nestlé ditches Aimmune’s peanut allergy drug Palforzia

After lackluster sales dampened the initial enthusiasm that came with a $2.1 billion acquisition, Nestlé has finally found a new owner for its peanut allergy drug Palforzia. Nestlé has divested Palforzia to U.S.-based allergy specialist Stallergenes Greer for an undisclosed sum, the food giant said Tuesday. The transaction closed when the two companies signed the agreement. Nestlé will receive milestone payments and royalties from Stallergenes Greer. The deal comes later than expected. Back in November, Nestlé announced a strategic review of Palforzia, citing slower-than-expected uptake by patients and doctors. At that time, the review was expected to be done in the first half of 2023. Palforzia became the first drug approved by the FDA for peanut allergy in children in January 2020. Back then, Evaluate Pharma projected that the drug could reach $1.28 billion in sales by 2024. Seeing Palforzia’s value in its food allergy portfolio, Nestlé in August 2020 ...
- Source: drugdu
- 154
- September 7, 2023
Novartis Confirms Sandoz Spin-Off Plans, Sets Oct. 4 Completion Date

By Tristan Manalac Pictured: Novartis Institutes for BioMedical Research building in California/iStock, JHVEPhoto Novartis on Tuesday confirmed that it is pushing through with the spin-off of its generics and biosimilars division Sandoz, pending the final approval of its shareholders. To secure approval, the Swiss pharma group will hold an extraordinary general meeting set for Sept. 15. If given the go-ahead, Novartis expects to complete Sandoz’s spin-off “on or around” Oct. 4, the company said in Tuesday’s announcement. Novartis is also planning to list Sandoz on the SIX Swiss Exchange, with an American Depository Receipt (ADR) program in the U.S., for which the pharma group will likewise need to secure regulatory approvals. Novartis first launched a strategic review of its generics unit in October 2021, when it announced that it was exploring options for the business moving forward—including a potential sale. At the time, Sandoz was seeing better volume sales figures ...
- Source: drugdu
- 104
- September 7, 2023
About Half of MA Beneficiaries Leave Their Plan After 5 Years

As Medicare Advantage enrollment grows, a new study found that about half of Medicare Advantage enrollees disenroll from their plan after five years. The study was conducted by researchers at Brown University School of Public Health and was published in JAMA Health Forum. It examined nearly 82.4 million individuals “with any” Medicare Advantage enrollment between 2011 and 2020. The researchers found that after one year of enrolling in a Medicare Advantage plan, 13.2% of non-dually enrolled beneficiaries disenrolled from their plan, and 15.9% of dually enrolled beneficiaries disenrolled from their plan. Then, after five years, 48.3% of non-dually enrolled beneficiaries left their contract, as did 53.4% of dually enrolled beneficiaries. “On one hand, these levels of disenrollment may be indicative of a healthy [Medicare Advantage] marketplace, with beneficiaries freely choosing contracts and making different elections if better choices become available,” the study said. “On the other hand, this could also ...
- Source: drugdu
- 124
- September 6, 2023
5 Foundational Capabilities Needed for Implementing a Value-Based Care Program

Ready or not, value-based care (VBC) is here. For providers and medical practices, the stakes are high. Despite spending more money per person on healthcare than any country in the world, patients in the United States experience the worst outcomes overall of any high-income nation. The problem? The traditional fee-for-service model has created a misalignment between financial incentives and desired outcomes by compensating clinicians for each service delivered, encouraging greater volume rather than improved health outcomes. VBC seeks to restore that alignment, rewarding practices and providers for delivering measurable health outcomes and cost-effective care. Moreover, practices that embrace VBC can open significant opportunities to improve the health outcomes of their patients while preserving their practice’s profit margins under a stagnating fee-for-service landscape for reimbursement rates and increasing medical inflation. According to CMS.gov data, physician and clinical services expenditures sat at 5.6% in 2021, down 1% from 2020, while spending on ...
- Source: drugdu
- 171
- September 6, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.